Multidrug-resistant viridans streptococcus (MDRVS) osteomyelitis of the mandible successfully treated with moxifloxacin.
Multidrug-resistant viridans group streptococcus (MDRVS) strains have emerged as important pathogens. Treatment of MDRVS infections is problematic. The use of fluoroquinolones for treatment of MDRVS osteomyelitis has not been established. We present the first case of MDRVS osteomyelitis of the mandible successfully treated with sequential intravenous then oral moxifloxacin, and review the literature on the subject.
Ang
Jocelyn Y
JY
Wayne State University, Carman and Ann Adams Department of Pediatrics, Division of Infectious Diseases, Children's Hospital of Michigan, Detroit, MI 48201, USA. jang@med.wayne.edu
Asmar
Basim I
BI
D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001372:Aza Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003646:Debridement; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008336:Mandibular Diseases / Q000188:drug therapy* / Q000382:microbiology* / Q000601:surgery; D000077266:Moxifloxacin; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology* / Q000601:surgery; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013290:Streptococcal Infections / Q000188:drug therapy*; D034363:Viridans Streptococci / Q000187:drug effects
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin